

September 22, 2023

To,

The Manager- Listing Department,
National Stock Exchange of India Limited,
Exchange Plaza, Plot No. C/1, Block-G,
Bandra - Kurla Complex, Bandra (E),
Mumbai - 400051

Scrip Code: REMUS

Dear Sir/Madam,

Sub: Proceedings of 08TH (Eighth) Annual General Meeting of the Company

Pursuant to Regulation 30 read with Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith summary of proceedings of 08th Annual General Meeting of the members of the Company held on Friday, 22nd September, 2023 at 09:30 A.M. (IST) through Video Conference (VC) / Other Audio-Visual Means (OAVM) in compliance with the MCA General Circulars dated 8th April, 2020, 13th April, 2020, 5th May, 2020, 13th January, 2021, 14th December, 2021, 5th May, 2022, 28th December, 2022 and any further amendments/clarifications thereof issued by the Ministry of Corporate Affairs (collectively referred to as "MCA Circulars"), Circulars dated 12th May, 2020 and 15th January, 2021, 13th May, 2022 and 5th January, 2023 ("SEBI Circulars") issued by the Securities and Exchange Board of India and relevant provisions of the Companies Act, 2013 and SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations").

Kindly take the above intimation on your record.

Thanking you,

Yours Sincerely,
For Remus Pharmaceuticals Limited

Arpit Deepakkumar Shah
Managing Director
DIN:07214641



Encl.: a/a

Remus Pharmaceuticals Limited

REGISTERED OFFICE: 1101 to 1103, South Tower, One42, B/H Ashok Vatika, Nr. Jayantilal Park BRTS, Ambli Bopal Road, Ahmedabad-380054, Gujarat, India.

P: 079 2999 9857

USA OFFICE: 5900 Balcones Drive, STE 100 Austin, TX 78731

P: +1 6096 320 320

E. remus@remuspharma.com | W. www.remuspharma.com

GST NO: 24AAHCR4771P2ZQ | CIN NO: U24232GJ2015PLC084536

SUMMARY OF THE PROCEEDINGS OF THE EIGHTH ANNUAL GENERAL MEETING OF THE MEMBERS OF REMUS PHARMACEUTICALS LIMITED HELD ON FRIDAY, SEPTEMBER 22, 2023 AT 09:30 A.M.(I.S.T) THROUGH VIDEO CONFERENCE

The 08THAnnual General Meeting (“AGM”) of the Members of the Company was held on Friday, 22nd September, 2023 at 09:30 A.M. through Video Conference (VC).

The AGM commenced at 09.31 a.m. IST and concluded at 09.46 a.m. IST.

The following were present at the AGM:

Mr. Swapnil Jatinbhai Shah	Chairman and Whole Time Director
Mr. Arpit Deepakkumar Shah	Managing Director
Ms. Roma Vinodbhai Shah	Whole Time Director
Mrs. Anar Swapnil Shah	Whole Time Director
Mr. Vishrut Pathak	Non- Executive Independent Director – Chairperson of Audit Committee
Mr. Balwant Purohit	Non- Executive Independent Director – Chairperson of Stakeholders Relationship Committee
Ms. Sanjana Sanjeev Shah	Non- Executive Independent Director – Chairperson of Nomination and Remuneration Committee
Ms. Anjali Shah	Chief Financial Officer
Ms. Deval Patel	Company Secretary and Compliance Officer
Mr. Satwik Durkal	Partner, M/s. Parikh & Majumdar, Statutory Auditors of the Company
Mr. Tapan Shah	Proprietor, Tapan Shah- Company Secretaries Scrutinizer of the AGM

Mr. Swapnil Shah, Chairman of the Company chaired the AGM.

11 members were present at the AGM.

The Company Secretary welcomed all the shareholders and informed that the 08thAnnual General Meeting of the company is being conducted through VC/OAVM pursuant to the MCA Circulars and SEBI Circulars.

Remus Pharmaceuticals Limited

REGISTERED OFFICE: 1101 to 1103, South Tower, One42, B/H Ashok Vatika, Nr. Jayantilal Park BRTS, Ambli Bopal Road, Ahmedabad-380054, Gujarat, India.

P: 079 2999 9857

USA OFFICE:

5900 Balcones Drive, STE 100 Austin, TX 78731

P: +1 6096 320 320

E. remus@remuspharma.com | W. www.remuspharma.com

GST NO: 24AAHCR4771P2ZQ | CIN NO: U24232GJ2015PLC084536

The Company Secretary introduced other panel members including the Board of Directors, Statutory Auditors and Scrutinizer who were attending the meeting from their respective locations in Ahmedabad. The members were briefed on details relating to their participation at the Meeting through audio-visual means.

After ascertaining from the Company Secretary that the requisite quorum was present at the AGM, the Chairman called the meeting to order and asked Company Secretary to continue with the rest of the proceedings of the meeting.

With the consent of the members present, the Notice of 08th Annual General Meeting along with the Annual Report which consist of Audited Financial Statements, Directors' and Auditors' Report for the year ended March 31, 2023 was taken as read.

The Chairman of the Company then delivered his speech, which included brief overview of the Company's performance, development & growth of pharmaceutical industry and Company's prospects.

The Company Secretary thereafter informed the members the following:

- Pursuant to the provisions of Section 108 of the Companies Act, 2013 read with Rule 20 of the Companies (Management and Administration) Rules, 2014 as amended from time to time and Regulation 44 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and the Secretarial Standard on General Meetings issued by the Institute of Company Secretaries of India, the Company had provided remote e-voting facility to the members of the Company in respect of business to be transacted at the 08th AGM of the Company.
- The e-voting period commenced on Tuesday, 19th September, 2023 (at 9:00 a.m. IST) and ended on Thursday, 21st September, 2023 (at 5:00 p.m. IST).
- Members who had not casted their vote through e-voting facility are entitled to cast their votes in respect of the resolutions proposed in the notice during the AGM. Facility to vote during AGM was provided to Members through Link Intime India Private Limited. The e-voting process will continue for fifteen minutes after the conclusion of AGM and it will be disabled thereafter.
- Mr. Tapan Shah, Practising Company Secretary, who is the Scrutinizer for the e-voting process (Remote e-voting and AGM e-voting), was also appointed as the Scrutinizer to scrutinize the e-voting process in a fair and transparent manner.

The resolutions proposed were as follows:

Ordinary Business:

1. To receive, consider and adopt the Audited Financial Statements of the Company for the Financial Year ended 31st March, 2023 and the Report of the Board of Directors and Auditors thereon. **(Ordinary Resolution)**

Remus Pharmaceuticals Limited

REGISTERED OFFICE: 1101 to 1103, South Tower, One42, B/H Ashok Vatika, Nr. Jayantilal Park BRTS, Ambli Bopal Road, Ahmedabad-380054, Gujarat, India.

P: 079 2999 9857

USA OFFICE: 5900 Balcones Drive, STE 100 Austin, TX 78731

P: +1 6096 320 320

E. remus@remuspharma.com | W. www.remuspharma.com

GST NO: 24AAHCR4771P2ZQ | CIN NO: U24232GJ2015PLC084536

2. To declare dividend of Rs.02/- (Rupees Two Only) Per Equity Share for the Financial Year 2022-23. **(Ordinary Resolution)**
3. To appoint a Director in place of Ms. Roma Vinodbhai Shah (DIN: 07214632), who retires by rotation and being eligible, offers herself for re-appointment. **(Ordinary Resolution)**

The Company Secretary informed the members that the results will be declared upon receipt of consolidated scrutinizer's report within statutory time period. She further informed that the results shall also be uploaded on the Company's website www.remuspharma.com together with the consolidated report of the Scrutinizer and shall also be available on the website of National Stock Exchange of India Limited .

With the permission of the Chairman, Company Secretary announced formal closure of the 8th Annual General Meeting of the Company.

The Chairman and Company Secretary thanked the members for participating in the meeting.

For Remus Pharmaceuticals Limited

Arpit Deepakkumar Shah
Managing Director
DIN:07214641

Place: Ahmedabad



Remus Pharmaceuticals Limited

REGISTERED OFFICE: 1101 to 1103, South Tower, One42, B/H Ashok Vatika, Nr. Jayantilal Park BRTS, Ambli Bopal Road, Ahmedabad-380054, Gujarat, India.

P: 079 2999 9857

USA OFFICE: 5900 Balcones Drive, STE 100 Austin, TX 78731

P: +1 6096 320 320

E. remus@remuspharma.com | W. www.remuspharma.com

GST NO: 24AAHCR4771P2ZQ | CIN NO: U24232GJ2015PLC084536